• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Clinical course and prognostic factors following bone recurrence from breast cancer.乳腺癌骨转移复发后的临床病程及预后因素
Br J Cancer. 1998;77(2):336-40. doi: 10.1038/bjc.1998.52.
2
[Clinicopathological features and prognostic factors of breast cancer patients with inguinal lymph node metastases: a report of 17 cases].腹股沟淋巴结转移乳腺癌患者的临床病理特征及预后因素:附17例报告
Zhonghua Zhong Liu Za Zhi. 2013 Mar;35(3):207-11. doi: 10.3760/cma.j.issn.0253-3766.2013.03.010.
3
Age at diagnosis and distant metastasis in breast cancer--a surprising inverse relationship.乳腺癌的诊断年龄与远处转移——出人意料的反比关系。
Eur J Cancer. 2014 Jul;50(10):1697-1705. doi: 10.1016/j.ejca.2014.04.002. Epub 2014 Apr 23.
4
Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.新辅助化疗的临床和病理反应与局部晚期乳腺癌预后的关系
J Surg Oncol. 2002 May;80(1):4-11. doi: 10.1002/jso.10090.
5
[Lobular invasive breast cancer prognostic factors: About 940 patients].小叶浸润性乳腺癌的预后因素:约940例患者
Gynecol Obstet Fertil. 2015 Nov;43(11):712-7. doi: 10.1016/j.gyobfe.2015.09.007. Epub 2015 Oct 16.
6
Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.影响乳腺癌骨转移发生的临床参数评估
BMC Cancer. 2016 May 12;16:307. doi: 10.1186/s12885-016-2345-7.
7
[Treatment outcomes and clinicopathologic characteristics of advanced triple-negative breast cancer patients].[晚期三阴性乳腺癌患者的治疗结果及临床病理特征]
Zhonghua Zhong Liu Za Zhi. 2011 May;33(5):381-4.
8
Breast cancer in women aged 35 and under: prognosis and survival.35岁及以下女性的乳腺癌:预后与生存情况
J R Coll Surg Edinb. 2002 Oct;47(5):693-9.
9
[Proliferation index and its prognostic value in invasive ductal breast carcinoma].[增殖指数及其在浸润性导管癌中的预后价值]
Ann Acad Med Stetin. 2009;55(1):22-30.
10
Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.乳腺癌远处转移的器官趋向性和预后标志物不一致:是事实还是虚构?一项临床病理分析。
Hum Pathol. 2012 Mar;43(3):398-404. doi: 10.1016/j.humpath.2011.05.009. Epub 2011 Aug 12.

引用本文的文献

1
Single-Cell Analysis Reveals that Vitamin C Inhibits Bone Metastasis of Renal Cancer via Cell Cycle Arrest and Microenvironment Remodeling.单细胞分析表明,维生素C通过细胞周期阻滞和微环境重塑抑制肾癌的骨转移。
Adv Sci (Weinh). 2025 Aug;12(30):e01011. doi: 10.1002/advs.202501011. Epub 2025 May 28.
2
The Breast to Bone (B2B) Cohort Study to Prevent, Detect and Improve Treatment of Metastatic Disease: Baseline Assessment, Description and Progress.预防、检测和改善转移性疾病治疗的乳腺至骨(B2B)队列研究:基线评估、描述与进展
Int J Environ Res Public Health. 2025 Feb 8;22(2):242. doi: 10.3390/ijerph22020242.
3
Spinal Metastasis Pain Surveillance: A Comprehensive Imaging-Based Tool Design for Evaluating Metastatic Burden and Guiding Therapeutic Strategies.脊柱转移瘤疼痛监测:一种基于影像学的综合工具设计,用于评估转移负担和指导治疗策略。
Int J Med Sci. 2025 Jan 13;22(3):708-715. doi: 10.7150/ijms.103916. eCollection 2025.
4
Differential bone morphology and hypoxia activity in skeletal metastases of ER and ER breast cancer.雌激素受体(ER)阳性和 ER 阴性乳腺癌骨转移的骨骼形态差异和缺氧活性。
Commun Biol. 2024 Nov 21;7(1):1545. doi: 10.1038/s42003-024-07247-6.
5
Clinical practice guidelines for full-cycle standardized management of bone health in breast cancer patients.乳腺癌患者骨健康全周期标准化管理临床实践指南
Cancer Innov. 2024 Feb 29;3(1):e111. doi: 10.1002/cai2.111. eCollection 2024 Feb.
6
Estradiol induces bone osteolysis in triple-negative breast cancer via its membrane-associated receptor ERα36.雌二醇通过其膜相关受体ERα36在三阴性乳腺癌中诱导骨溶解。
JBMR Plus. 2024 Mar 26;8(5):ziae041. doi: 10.1093/jbmrpl/ziae041. eCollection 2024 May.
7
Beyond boundaries: unraveling innovative approaches to combat bone-metastatic cancers.超越界限:揭示创新方法以应对骨转移性癌症。
Front Endocrinol (Lausanne). 2024 Jan 8;14:1260491. doi: 10.3389/fendo.2023.1260491. eCollection 2023.
8
Siglec-15/sialic acid axis as a central glyco-immune checkpoint in breast cancer bone metastasis.Siglec-15/唾液酸轴作为乳腺癌骨转移中的中央糖免疫检查点。
Proc Natl Acad Sci U S A. 2024 Jan 30;121(5):e2312929121. doi: 10.1073/pnas.2312929121. Epub 2024 Jan 22.
9
Predictive and prognostic biomarkers of bone metastasis in breast cancer: current status and future directions.乳腺癌骨转移的预测和预后生物标志物:现状与未来方向
Cell Biosci. 2023 Dec 1;13(1):224. doi: 10.1186/s13578-023-01171-8.
10
Relationship Between Metabolic Activity, Cellularity, Histopathological Features of Primary Tumors and Distant Metastatic Potential in Breast Cancer.乳腺癌原发肿瘤的代谢活性、细胞密度、组织病理学特征与远处转移潜能之间的关系
Mol Imaging Radionucl Ther. 2023 Oct 20;32(3):195-205. doi: 10.4274/mirt.galenos.2022.60024.

本文引用的文献

1
Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.乳腺癌的组织学分级与预后;对1409例病例的研究,其中359例已随访15年。
Br J Cancer. 1957 Sep;11(3):359-77. doi: 10.1038/bjc.1957.43.
2
Effects of bone metastases on bone metabolism: implications for diagnosis, imaging and assessment of response to cancer treatment.骨转移对骨代谢的影响:对癌症治疗诊断、成像及疗效评估的意义
Cancer Treat Rev. 1996 Jul;22(4):289-331. doi: 10.1016/s0305-7372(96)90021-3.
3
Use of bisphosphonates in cancer patients.
Cancer Treat Rev. 1996 Jul;22(4):265-87. doi: 10.1016/s0305-7372(96)90020-1.
4
Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.帕米膦酸盐在降低乳腺癌伴溶骨性骨转移患者骨骼并发症方面的疗效。方案19阿仑膦酸钠乳腺癌研究组
N Engl J Med. 1996 Dec 12;335(24):1785-91. doi: 10.1056/NEJM199612123352401.
5
Delay in progression of bone metastases in breast cancer patients treated with intravenous pamidronate: results from a multinational randomized controlled trial. The Aredia Multinational Cooperative Group.静脉注射帕米膦酸治疗的乳腺癌患者骨转移进展延迟:一项多国随机对照试验的结果。阿仑膦酸钠多国合作组
J Clin Oncol. 1996 Sep;14(9):2552-9. doi: 10.1200/JCO.1996.14.9.2552.
6
Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer.口服氯膦酸盐治疗乳腺癌骨转移患者的双盲对照试验。
J Clin Oncol. 1993 Jan;11(1):59-65. doi: 10.1200/JCO.1993.11.1.59.
7
High-dose intravenous pamidronate for metastatic bone pain.大剂量静脉注射帕米膦酸盐治疗转移性骨痛。
Br J Cancer. 1994 Sep;70(3):554-8. doi: 10.1038/bjc.1994.344.
8
The clinical course of bone metastases from breast cancer.乳腺癌骨转移的临床病程。
Br J Cancer. 1987 Jan;55(1):61-6. doi: 10.1038/bjc.1987.13.
9
Bone metastases: pathogenesis, treatment, and rationale for use of resorption inhibitors.
Am J Med. 1987 Feb 23;82(2A):6-28. doi: 10.1016/0002-9343(87)90483-9.
10
Steroid hormone receptor activity of primary human breast cancer and pattern of first metastasis. The Breast Cancer Study Group.原发性人类乳腺癌的类固醇激素受体活性及首次转移模式。乳腺癌研究小组。
Breast Cancer Res Treat. 1991 Mar;18(1):27-32. doi: 10.1007/BF01975440.

乳腺癌骨转移复发后的临床病程及预后因素

Clinical course and prognostic factors following bone recurrence from breast cancer.

作者信息

Coleman R E, Smith P, Rubens R D

机构信息

YCRC Department of Clinical Oncology, Weston Park Hospital, Sheffield, UK.

出版信息

Br J Cancer. 1998;77(2):336-40. doi: 10.1038/bjc.1998.52.

DOI:10.1038/bjc.1998.52
PMID:9461007
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2151240/
Abstract

Three hundred and sixty-seven women presenting to the Breast Unit at Guy's Hospital between 1975 and 1990 whose first distant metastasis was in the skeleton were identified and the influence of a number of patient and tumour characteristics on the development and subsequent prognosis of bone metastases was assessed. One hundred and thirty-nine women had disease that remained clinically confined to the skeleton. They were more likely to be older, with lobular carcinoma and to have presented initially with little or no axillary lymph node involvement. The 228 women who subsequently developed disease at extra-osseus sites were more likely to have poorly differentiated ductal tumours and heavy lymph node involvement at primary diagnosis. On multivariate analysis, the clinical and pathological factors of greatest prognostic importance for survival after the development of bone metastases were histological grade (P = < 0.0001), oestrogen receptor status (P = < 0.0001), bone disease at initial presentation (P = < 0.0001), disease-free interval (P = 0.002) and age (P = 0.006).

摘要

1975年至1990年间,盖伊医院乳腺科共收治了367名女性患者,她们首次出现的远处转移部位均在骨骼,研究人员对一系列患者和肿瘤特征对骨转移发生及后续预后的影响进行了评估。其中139名女性患者的疾病在临床上局限于骨骼。她们更有可能年龄较大,患有小叶癌,且最初就诊时腋窝淋巴结受累较少或无受累。随后在骨外部位出现疾病的228名女性患者,在初次诊断时更有可能患有低分化导管肿瘤且淋巴结受累严重。多因素分析显示,骨转移发生后对生存预后最重要的临床和病理因素为组织学分级(P = < 0.0001)、雌激素受体状态(P = < 0.0001)、初次就诊时的骨疾病情况(P = < 0.0001)、无病间期(P = 0.002)和年龄(P = 0.006)。